Web Summary
Q1: What is the address of Molecular Cyclotrons Pvt Ltd?
A1: The address of Molecular Cyclotrons Pvt Ltd is 251A, Molecular Multispeciality Hospital, Belbo – LNG Road, Puthuvype, Vypin, Ernakulam, Kerala, India 682 508.
Q2: What type of products does Molecular Cyclotrons Pvt Ltd produce?
A2: Molecular Cyclotrons Pvt Ltd produces PET radiopharmaceuticals, which are used in the diagnosis and staging of cancer, as well as for the diagnosis of neurological diseases.
Q3: In what year was Molecular Cyclotrons Pvt Ltd commissioned?
A3: Molecular Cyclotrons Pvt Ltd was commissioned in 2016 as the first medical cyclotron facility in Kerala.
Q4: What is the certification status of Molecular Cyclotrons Pvt Ltd's laboratory?
A4: The European standard laboratory of Molecular Cyclotrons Pvt Ltd is licensed by the Atomic Energy Regulatory Board (AERB) of India and certified in Good Manufacturing Practices (GMP) by TUV Austria Bureau of Inspection and Certification Pvt Ltd.
Q5: What is the primary product of Molecular Cyclotrons Pvt Ltd?
A5: The primary product of Molecular Cyclotrons Pvt Ltd is 18FFDG, a radiopharmaceutical widely used in the PET/CT scan for diagnosis and staging of cancer.
Q6: How many PET doses does Molecular Cyclotrons Pvt Ltd deliver per year?
A6: Molecular Cyclotrons Pvt Ltd delivers more than forty thousand PET doses per year to various cancer hospitals in Kerala, Tamil Nadu, and abroad.
Q7: What is the vision and mission of Molecular Cyclotrons Pvt Ltd?
A7: The vision and mission of Molecular Cyclotrons Pvt Ltd is to be perceived by customers as a radiopharmaceutical manufacturer whose products, service, and support exceed those of others in the same field, while aiming to comply with all safety standards set by the Atomic Energy Regulatory Board.
Q8: What is the contact information for Molecular Cyclotrons Pvt Ltd?
A8: The contact information for Molecular Cyclotrons Pvt Ltd includes phone number (not provided), email address cyclotron@molecularglobal.com, and a feedback form on their website.